Abstract
Despite the increasing burden of ill health attributable to chronic kidney disease, appropriate pharmacotherapy has been inadequate. Based on trials in the 1990s and 2000s,1 guidelines recommend renin angiotensin system (RAS) inhibition to reduce progression of chronic kidney disease and its associated cardiovascular risk. However, the global burden of chronic kidney disease continues to increase.1 Furthermore, data from the US CURE-CKD registry highlights that uptake of chronic kidney disease management strategies is low, with only around 21% of patients prescribed RAS inhibitors between 2006 and 2017.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
